Neumora Therapeutics Inc. (NASDAQ: NMRA) on Monday, plunged -3.42% from the previous trading day, before settling in for the closing price of $12.27. Within the past 52 weeks, NMRA’s price has moved between $8.33 and $21.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 59.37%. With a float of $54.91 million, this company’s outstanding shares have now reached $158.83 million.
The firm has a total of 124 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc. (NMRA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Neumora Therapeutics Inc. is 65.69%, while institutional ownership is 27.63%. The most recent insider transaction that took place on Oct 18 ’24, was worth 239,319. In this transaction Director of this company sold 14,049 shares at a rate of $17.03, taking the stock ownership to the 20,100 shares. Before that another transaction happened on Oct 17 ’24, when Company’s Director sold 7,739 for $17.01, making the entire transaction worth $131,643. This insider now owns 20,100 shares in total.
Neumora Therapeutics Inc. (NMRA) Recent Fiscal highlights
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1.14 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.36) by -0.78. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.37% per share during the next fiscal year.
Neumora Therapeutics Inc. (NASDAQ: NMRA) Trading Performance Indicators
Neumora Therapeutics Inc. (NMRA) is currently performing well based on its current performance indicators. A quick ratio of 17.22 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.74, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.55 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc. (NMRA)
Analysing the last 5-days average volume posted by the [Neumora Therapeutics Inc., NMRA], we can find that recorded value of 1.27 million was better than the volume posted last year of 0.7 million. As of the previous 9 days, the stock’s Stochastic %D was 3.91%. Additionally, its Average True Range was 1.00.
During the past 100 days, Neumora Therapeutics Inc.’s (NMRA) raw stochastic average was set at 39.74%, which indicates a significant increase from 1.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.57% in the past 14 days, which was higher than the 62.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.93, while its 200-day Moving Average is $12.74. Now, the first resistance to watch is $12.48. This is followed by the second major resistance level at $13.10. The third major resistance level sits at $13.47. If the price goes on to break the first support level at $11.49, it is likely to go to the next support level at $11.12. Now, if the price goes above the second support level, the third support stands at $10.50.
Neumora Therapeutics Inc. (NASDAQ: NMRA) Key Stats
Market capitalization of the company is 1.90 billion based on 159,524K outstanding shares. Right now, sales total 0 K and income totals -235,930 K. The company made 0 K in profit during its latest quarter, and -58,700 K in sales during its previous quarter.
